ACC 2022: Late-breaking Science Video Collection

Published: 05 April 2022

  • Views:

    Views Icon 7614

  • Likes:

    Heart Icon 7
Average (ratings)
No ratings
Your rating
View Transcript Download Transcript

Overview

Our regular review series View from the Thoraxcenter hosted by Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) provide a concise analysis of the late-breaking science results and spotlight impactful data. 

For a deeper dive into key clinical trial data, Dr Harriette Van Spall (McMaster University, Hamilton, CA)talks with principal investigators in her regular Late-Breaker Discussion Series. 

Short, accessible Expert Interviews were conducted with select faculty focusing on the results, applicability, and impact on future research.

More from this programme

Part 1

View from the Thoraxcenter

In this concise episode of View from the Thoraxcenter, Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) offer their analysis of the late-breaking trials that will be presented at ACC 2022.
2 sessions
ACC 22 Late-breaking Science Preview Watch now
ACC.22 Late-breaking Science Wrap-Up Watch now

Part 2

Late-breaker Discussion Series

Host, Dr Harriette Van Spall interviews the late-breaker presenters of ACC Scientific Sessions 2022.
4 sessions
ACC 2022 Late-breaker Discussion: The SODIUM-HF Trial Watch now
ACC 2022 Late-breaker Discussion: The SuperWIN Trial Watch now
ACC 22 Late-breaker Discussion: The PROMPT-HF Trial Watch now
ACC 22 Late-breaker Discussion: The DIAMOND Trial Watch now

Part 3

Expert Interviews

19 sessions
ACC 22: Findings from the VALOR-HCM Trial Watch now
ACC 22: MAVA-LTE Shows Improvement in NYHA Class in Patients Treated with Mavacamten Watch now
ACC 22: Results From the PACIFIC AF Trial Watch now
ACC 22: FAME 3 Suggests CABG Outperforms FFR-Guided PCI in Patients with Multivessel Disease Watch now
ACC 22: Results from the TRANSLATE-TIMI 70 Trial Watch now
ACC 22: Results from the POISE-3 Trial Watch now
ACC 22: ICD Shock Therapies and the Burden of Ventricular Tachycardia Watch now
ACC 22: PACMAN-AMI Shows Reduced Plaque Regression in AMI Patients Treated with Alirocumab Watch now
ACC 22: Magnitude & Duration of Effects of a siRNA Targeting Lp(a) Watch now
ACC 22: Results From a sub-study of the POISE-3 Trial Watch now
ACC 22: Findings from the CoreValve US Pivotal & SURTAVI Trials Watch now
ACC 22: ADAPT-TAVR Shows SLT Does Not Affect CO for Patients After TAVR Watch now
ACC 22: Results From the Chocolate-Touch Study Watch now
ACC 22: Results from the GIPS-IV Trial Watch now
ACC 22: FFR vs. IVUS-guided PCI in Intermediate Coronary Artery Stenosis: The FLAVOUR Trial Watch now
ACC 22: Results From the EMPULSE Study – Empagliflozin Proves Beneficial for Patients With HF Watch now
ACC 22: Secondary Analysis of CANTOS Finds LDL & HDL Predict Residual Risk of Atherosclerotic Events Watch now
ACC 22: 3-year Efficacy Outcomes from the SPYRAL HTN-ON MED Med Pilot Study Watch now
2022 AHA/ACC/HFSA Guideline for HF Management: Highlights & Implementation Watch now

Part 4

Late-breaking Highlights

3 sessions
ACC 22: 3 Trials That Will Change Your Practice with Dr Purvi Parwani Watch now
ACC 22: 5 Trials That Will Change Your Practice with Interventionalist, Dr Mirvat Alasnag Watch now
4 Lipid Late-breaker Highlights from ACC.22 with Dr Erin Michos Watch now

Faculty Biographies

Michelle Kittleson

Michelle Kittleson

Cardiologist & Professor of Medicine

Dr Michelle Kittleson is Professor of Medicine at Cedars-Sinai and Director of Education in Heart Failure and Transplantation at the Smidt Heart Institute.  She graduated from Harvard College and received her medical degree from Yale University.  She completed residency training at Brigham and Women's Hospital and cardiology fellowship at Johns Hopkins, where she also received a PhD in Clinical Investigation.  

Dr Kittleson is Interim Editor-in-Chief of the Journal of Heart and Lung Transplantation, on writing committees for the ACC/AHA Hypertrophic Cardiomyopathy Guidelines and the ACC/AHA/HFSA HF Guidelines, Co Editor-in-Chief for the ACC Heart Failure Self-Assessment Program, and on the Board of Directors for the Heart Failure Society of America.  Her essays have appeared in the New England Journal of Medicine, Annals of Internal Medicine…

View full profile

Transcript

- I'm Michelle Kittleson, I'm a heart failure transplant cardiologist, at Cedar-Sinai in Los Angeles, California, and I'm here to talk about the new 2022 ACC/AHA/HFSA guideline for the management of heart failure.

Highlights of the New 2022 AHA/ACC/HFSA Guideline for the Management of HF

So I'm particularly excited about four advances in the new guidelines. Number one, I think it's fantastic that the categorization of ejection fraction includes the 41 to 49% particularly, making a special category and distinction for heart failure with improved ejection fraction, because it's so important to follow your patient's trajectories, and if you achieve success, improvement and ejection fraction, don't stop the guideline directed medical therapy that likely got them there. Which leads me to my second advance that I'm very excited about, which is the fact that the guidelines truly support and celebrate the importance of quadruple therapy, the four essential pillars of guideline directed medical therapy best given with an angiotensin receptor neprilysin inhibitor, evidence based beta blocker, mineralocorticoid antagonist and SGLT2 inhibitor. The third area I'm very excited about is cardiac amyloidosis, which has now been given an entire section in the new guidelines for diagnosis and treatment really indicating how important this has become in the field of cardiology, with under recognised prevalence with ease of diagnosis, non-invasively for TTR amyloidosis and now an FDA approved therapy to improve survival and reduce heart failure hospitalizations in patients with amyloidosis. And finally, I'm so excited that the new guidelines include value statements for many therapies, balancing the costs and the benefits. And in addition, focuses on vulnerable populations and disparities and strategies to a improve them.

Strategies that can Help Clinicians to Incorporate the Recommendations into Clinical Practice

You know, I think a guideline document can be very daunting over a hundred pages, almost 200 recommendations, countless tables, figures. How do you navigate this? So I have a strategy. Number one, whenever you see a new guideline document, read the top 10 take home messages that tell you what the architects of the guideline found most important. Number two, look through the table of contents get a sense of what's actually in there. Number three, look at the tables and the figures, so high yield for diagnostic therapeutic algorithms. Then the next time you're faced with a patient, you don't know what to do. You know that your answer may be in the guidelines, use the search function, thank goodness for the search function and hone in on the area it can help you. I think if you use the guidelines as your trusted and reliable resource of how to care for patients and know to feel comfortable going to them, you will more easily incorporate them in your clinical practice.

Barriers and Opportunities

You know, there's no question that there exists therapeutic inertia on the part of clinicians, on the part of patients, on the part of systems. But I would say whenever you encounter a patient with heart failure the most important questions to ask yourself are if this is heart failure with improved ejection fraction, make sure you don't stop guideline directive medical therapy. If there's a patient with heart failure with reduced EF are they on the four essential pillars? And if not, why not? If this patient has a preserved ejection fraction, am I missing cardiac amyloidosis? And with every patient, is there something I can do as their clinician to assist with these issues of disparity and improve their lives.